Abstract: The present invention relates to novel therapeutic compounds, known as RNAi agents, that decrease expression of the FAS receptor (expressed by the FAS gene), thereby decreasing expression of FAS mRNA and protein expression. Such RNAi agents are useful in the treatment of diseases involving the regulation of FAS expression and function, such as autoimmune hepatitis.
| # | Name | Date |
|---|---|---|
| 1 | 202517061137-STATEMENT OF UNDERTAKING (FORM 3) [26-06-2025(online)].pdf | 2025-06-26 |
| 3 | 202517061137-Sequence Listing in txt [26-06-2025(online)].txt | 2025-06-26 |
| 4 | 202517061137-Sequence Listing in PDF [26-06-2025(online)].pdf | 2025-06-26 |
| 5 | 202517061137-REQUEST FOR EXAMINATION (FORM-18) [26-06-2025(online)].pdf | 2025-06-26 |
| 6 | 202517061137-PROOF OF RIGHT [26-06-2025(online)].pdf | 2025-06-26 |
| 7 | 202517061137-POWER OF AUTHORITY [26-06-2025(online)].pdf | 2025-06-26 |
| 8 | 202517061137-FORM 18 [26-06-2025(online)].pdf | 2025-06-26 |
| 9 | 202517061137-FORM 1 [26-06-2025(online)].pdf | 2025-06-26 |
| 10 | 202517061137-DECLARATION OF INVENTORSHIP (FORM 5) [26-06-2025(online)].pdf | 2025-06-26 |
| 11 | 202517061137-COMPLETE SPECIFICATION [26-06-2025(online)].pdf | 2025-06-26 |
| 12 | 202517061137-CLAIMS UNDER RULE 1 (PROVISIO) OF RULE 20 [26-06-2025(online)].pdf | 2025-06-26 |
| 13 | 202517061137-FORM 3 [01-09-2025(online)].pdf | 2025-09-01 |